Cargando…

Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity

Dr. Reddy's Laboratories rituximab (DRL_RI; Dr. Reddy's Laboratories SA, Basel, Switzerland) is under development as a rituximab biosimilar. Study RI‐01‐002 (Clinical Trials Registry ‐ India/2012/11/003129), comparing DRL_RI to the reference medicinal product (RMP) MabThera® (Roche, Grenza...

Descripción completa

Detalles Bibliográficos
Autores principales: Svensson, Robin J., Ooi, Qing Xi, Friberg, Lena E., Maharaj, Narendra, Reddy, Pramod Kumar, López‐Lázaro, Luis, Hansson, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931428/
https://www.ncbi.nlm.nih.gov/pubmed/36330695
http://dx.doi.org/10.1002/psp4.12885
_version_ 1784889248549175296
author Svensson, Robin J.
Ooi, Qing Xi
Friberg, Lena E.
Maharaj, Narendra
Reddy, Pramod Kumar
López‐Lázaro, Luis
Hansson, Emma
author_facet Svensson, Robin J.
Ooi, Qing Xi
Friberg, Lena E.
Maharaj, Narendra
Reddy, Pramod Kumar
López‐Lázaro, Luis
Hansson, Emma
author_sort Svensson, Robin J.
collection PubMed
description Dr. Reddy's Laboratories rituximab (DRL_RI; Dr. Reddy's Laboratories SA, Basel, Switzerland) is under development as a rituximab biosimilar. Study RI‐01‐002 (Clinical Trials Registry ‐ India/2012/11/003129), comparing DRL_RI to the reference medicinal product (RMP) MabThera® (Roche, Grenzach‐Wyhlen, Germany), demonstrated pharmacokinetic (PK) equivalence and showed comparable pharmacodynamic, efficacy, safety, and immunogenicity profiles. We used data from the same study to perform population PK and PK–pharmacodynamic analyses: first exploring possible factors influencing the PK similarity assessment between products and then performing simulations to investigate the impact of tumor size on rituximab PK. Nonlinear mixed‐effects models for PK, tumor size, tumor size–PK, and tumor response were developed independently. The final PK model included drug product as a dose‐scaling parameter and predicted a 6.75% higher dose reaching the system in RMP‐treated patients. However, when tumor size was included in the tumor size–PK model, the drug product effect was no longer observed. The model rather indicated that patients with larger tumor size have higher clearance. Further simulations confirmed that higher baseline tumor size is associated to slightly lower rituximab exposure. Tumor response, described by a continuous‐time Markov model, did not differ between drug products. Both had higher effects during the first 20 weeks of treatment. Also, the model described a subpopulation of nonresponders to treatment (42%) with faster transitions to a worse state. The different rituximab exposure initially detected between drug products (6.75%) was shown using PK/PK–pharmacodynamic analysis to be attributed to a tumor size imbalance between treatment groups. PK/PK–pharmacodynamic analyses may contribute to PK similarity assessments.
format Online
Article
Text
id pubmed-9931428
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99314282023-02-16 Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity Svensson, Robin J. Ooi, Qing Xi Friberg, Lena E. Maharaj, Narendra Reddy, Pramod Kumar López‐Lázaro, Luis Hansson, Emma CPT Pharmacometrics Syst Pharmacol Research Dr. Reddy's Laboratories rituximab (DRL_RI; Dr. Reddy's Laboratories SA, Basel, Switzerland) is under development as a rituximab biosimilar. Study RI‐01‐002 (Clinical Trials Registry ‐ India/2012/11/003129), comparing DRL_RI to the reference medicinal product (RMP) MabThera® (Roche, Grenzach‐Wyhlen, Germany), demonstrated pharmacokinetic (PK) equivalence and showed comparable pharmacodynamic, efficacy, safety, and immunogenicity profiles. We used data from the same study to perform population PK and PK–pharmacodynamic analyses: first exploring possible factors influencing the PK similarity assessment between products and then performing simulations to investigate the impact of tumor size on rituximab PK. Nonlinear mixed‐effects models for PK, tumor size, tumor size–PK, and tumor response were developed independently. The final PK model included drug product as a dose‐scaling parameter and predicted a 6.75% higher dose reaching the system in RMP‐treated patients. However, when tumor size was included in the tumor size–PK model, the drug product effect was no longer observed. The model rather indicated that patients with larger tumor size have higher clearance. Further simulations confirmed that higher baseline tumor size is associated to slightly lower rituximab exposure. Tumor response, described by a continuous‐time Markov model, did not differ between drug products. Both had higher effects during the first 20 weeks of treatment. Also, the model described a subpopulation of nonresponders to treatment (42%) with faster transitions to a worse state. The different rituximab exposure initially detected between drug products (6.75%) was shown using PK/PK–pharmacodynamic analysis to be attributed to a tumor size imbalance between treatment groups. PK/PK–pharmacodynamic analyses may contribute to PK similarity assessments. John Wiley and Sons Inc. 2022-12-25 /pmc/articles/PMC9931428/ /pubmed/36330695 http://dx.doi.org/10.1002/psp4.12885 Text en © 2022 Dr. Reddy's Laboratories SA. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research
Svensson, Robin J.
Ooi, Qing Xi
Friberg, Lena E.
Maharaj, Narendra
Reddy, Pramod Kumar
López‐Lázaro, Luis
Hansson, Emma
Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
title Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
title_full Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
title_fullStr Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
title_full_unstemmed Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
title_short Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
title_sort rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large b‐cell lymphoma: influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931428/
https://www.ncbi.nlm.nih.gov/pubmed/36330695
http://dx.doi.org/10.1002/psp4.12885
work_keys_str_mv AT svenssonrobinj rituximabpharmacokineticandpharmacokineticpharmacodynamicevaluationbasedonastudyindiffuselargebcelllymphomainfluenceoftumorsizeonpharmacokineticandassessmentofpharmacokineticsimilarity
AT ooiqingxi rituximabpharmacokineticandpharmacokineticpharmacodynamicevaluationbasedonastudyindiffuselargebcelllymphomainfluenceoftumorsizeonpharmacokineticandassessmentofpharmacokineticsimilarity
AT friberglenae rituximabpharmacokineticandpharmacokineticpharmacodynamicevaluationbasedonastudyindiffuselargebcelllymphomainfluenceoftumorsizeonpharmacokineticandassessmentofpharmacokineticsimilarity
AT maharajnarendra rituximabpharmacokineticandpharmacokineticpharmacodynamicevaluationbasedonastudyindiffuselargebcelllymphomainfluenceoftumorsizeonpharmacokineticandassessmentofpharmacokineticsimilarity
AT reddypramodkumar rituximabpharmacokineticandpharmacokineticpharmacodynamicevaluationbasedonastudyindiffuselargebcelllymphomainfluenceoftumorsizeonpharmacokineticandassessmentofpharmacokineticsimilarity
AT lopezlazaroluis rituximabpharmacokineticandpharmacokineticpharmacodynamicevaluationbasedonastudyindiffuselargebcelllymphomainfluenceoftumorsizeonpharmacokineticandassessmentofpharmacokineticsimilarity
AT hanssonemma rituximabpharmacokineticandpharmacokineticpharmacodynamicevaluationbasedonastudyindiffuselargebcelllymphomainfluenceoftumorsizeonpharmacokineticandassessmentofpharmacokineticsimilarity